m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03371)
Name
Recombinant human endostatin
Synonyms
Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn
    Click to Show/Hide
Status
Approved
TTD Drug ID
D05YAG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Beta-catenin (CTNNB1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). [2], [4]
RNA binding protein X (RBMX)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The RNA binding protein X (RBMX) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). [2], [5]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). [2], [4]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). [2], [6]
References
Ref 1 FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting Beta-catenin through mRNA demethylation. Mol Carcinog. 2018 May;57(5):590-597. doi: 10.1002/mc.22782. Epub 2018 Feb 1.
Ref 2 Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148. doi: 10.1038/s41467-019-11918-y.
Ref 3 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 4 Ethionine-mediated reduction of S-adenosylmethionine is responsible for the neural tube defects in the developing mouse embryo-mediated m6A modification and is involved in neural tube defects via modulating Wnt/Beta-catenin signaling pathway. Epigenetics Chromatin. 2021 Dec 4;14(1):52. doi: 10.1186/s13072-021-00426-3.
Ref 5 N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 2017 Jun 2;45(10):6051-6063. doi: 10.1093/nar/gkx141.
Ref 6 Loading MicroRNA-376c in Extracellular Vesicles Inhibits Properties of Non-Small Cell Lung Cancer Cells by Targeting YTHDF1. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820977525. doi: 10.1177/1533033820977525.